Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Rajkumar

Showing results (501-510 of 602) with videos related to

Pageof 61
Sort By:
Blood|January 7, 2006
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationAngela Dispenzieri, Martha Q Lacy, Jerry A Katzmann, et al.
Blood Advances|November 23, 2018
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myelomaMohammed A Aljama, M Hasib Sidiqi, Arjun Lakshman, et al.
British Journal of Haematology|July 13, 2019
Ten-year survivors in AL amyloidosis: characteristics and treatment patternEli Muchtar, Morie A Gertz, Martha Q Lacy, et al.
Blood Cancer Journal|February 18, 2025
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2024
Simplified Risk Stratification Model for Patients With Waldenström MacroglobulinemiaSaurabh Zanwar, Jennifer Le-Rademacher, Eric Durot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2020
Implications of MYC Rearrangements in Newly Diagnosed Multiple MyelomaNadine Abdallah, Linda B Baughn, S Vincent Rajkumar, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 6, 2019
Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction TherapyBharat Nandakumar, Shaji K Kumar, Angela Dispenzieri, et al.
The Lancet. Oncology|December 10, 2020
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 studyJacob P Laubach, Fredrik Schjesvold, Mário Mariz, et al.
Mayo Clinic Proceedings|March 6, 2021
Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent TherapyBharat Nandakumar, Shaji K Kumar, Angela Dispenzieri, et al.
American Journal of Hematology|August 12, 2017
Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trialsArjun Lakshman, Jithma P Abeykoon, Shaji K Kumar, et al.
Pageof 61

Showing results (501-510 of 602) with videos related to

Sort By:
Pageof 61
Blood|January 7, 2006
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationAngela Dispenzieri, Martha Q Lacy, Jerry A Katzmann, et al.
Blood Advances|November 23, 2018
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myelomaMohammed A Aljama, M Hasib Sidiqi, Arjun Lakshman, et al.
British Journal of Haematology|July 13, 2019
Ten-year survivors in AL amyloidosis: characteristics and treatment patternEli Muchtar, Morie A Gertz, Martha Q Lacy, et al.
Blood Cancer Journal|February 18, 2025
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2024
Simplified Risk Stratification Model for Patients With Waldenström MacroglobulinemiaSaurabh Zanwar, Jennifer Le-Rademacher, Eric Durot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2020
Implications of MYC Rearrangements in Newly Diagnosed Multiple MyelomaNadine Abdallah, Linda B Baughn, S Vincent Rajkumar, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 6, 2019
Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction TherapyBharat Nandakumar, Shaji K Kumar, Angela Dispenzieri, et al.
The Lancet. Oncology|December 10, 2020
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 studyJacob P Laubach, Fredrik Schjesvold, Mário Mariz, et al.
Mayo Clinic Proceedings|March 6, 2021
Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent TherapyBharat Nandakumar, Shaji K Kumar, Angela Dispenzieri, et al.
American Journal of Hematology|August 12, 2017
Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trialsArjun Lakshman, Jithma P Abeykoon, Shaji K Kumar, et al.
Pageof 61